Noel M.
- Country
- Ireland
- Department
- Respiratory Medicine
Research Overview
- A Phase 1 Study of AIR-001 in Adults with Alpha-1 Antitrypsin Deficiency
- Phase 2 Randomized Double‑Blind Study of VX-828/Deutivacaftor With and Without Tezacaftor in Adults with Cystic Fibrosis
- Phase 1/2 Open‑Label Multi‑Center Dose‑Escalation and Expansion Study of Intravenous TSRA‑196 in Adults with PiZZ‑Genotype Alpha‑1 Antitrypsin Deficiency‑Related Lung and/or Liver Disease
Data & Insights
Has run more than one trial at 12 of 48 partner sites.
Specializations
Alpha-1 Antitrypsin Deficiency Treatment
The investigator specializes in researching therapeutic approaches for Alpha-1 Antitrypsin Deficiency (AATD), focusing on both innovative inhalation therapies and novel drug compounds.
- Inhaled AAT therapy optimization
- Novel therapeutic compounds development
- Long-term treatment efficacy assessment
Their work encompasses evaluation of various administration routes for AATD treatments, including inhalation and systemic delivery methods.
Pulmonary Disease Management
The investigator focuses on treating AATD-associated lung diseases, with particular attention to pulmonary emphysema and airflow limitations.
- Respiratory function assessment
- Pulmonary disease progression monitoring
- Airflow limitation treatment
Their research integrates advanced therapeutic approaches for managing chronic respiratory conditions related to AATD.
Hepatic Disease Research
The investigator conducts studies on AATD-associated liver disease, examining innovative treatments for liver fibrosis and related complications.
- Liver fibrosis treatment evaluation
- Hepatic safety monitoring
- Novel liver therapeutics assessment
Their work includes evaluation of targeted therapies for AATD-related liver manifestations and disease progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.